KB-1209

GMA106-GLP1R-hIgG4-S228P

Background

GMA106 is Gmax's second generation mAb therapy for the treatment of obesity/T2DM/NASH. GMA106 is composed of an anti-GIPR antibody fused with a GLP-1 peptide. It can simultaneously interact with GLP-1R and GIPR and regulate both signaling pathways to synergistically suppress appetite, reduce blood glucose and fat accumulation, and improve insulin resistance.

Specifications

Catalog Number:
KB-1209
Cell Line Name:
GMA106-GLP1R-hIgG4-S228P
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GLP1R
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose.
Please enable JavaScript in your browser to complete this form.